Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Antitumoral Efficacy of Nivolumab After SIRT for the Treatment of Patients With HCC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of HCC based on histology or non-invasive criteria if cirrhotics. Patients with fibrolamellar carcinoma are not excluded.~* Cirrhosis absent, non-viral or due to hepatitis C or B virus infection. Subjects with chronic hepatitis B virus infection must be on effective antiviral therapy~* Preserved liver function (without cirrhosis or with compensated cirrhosis in Child Pugh Class A).~* ECOG performance status 0 or 1~* Willing to have a liver biopsy pre-treatment~* Considered candidates for locoregional therapy using SIR-Spheres based on~  * the absence of extrahepatic disease (patients with regional lymph nodes \< 2 cm in short axis are accepted)~ * unsuitability for liver resection or transplantation, or percutaneous ablation~ * considered not good candidates for TACE because they have; Single tumors larger than 5 cm. Multiple tumors that cannot be targeted superselectively. Unilobar tumors with segmental or lobar portal vein thrombosis.~* At least one measurable lesion by RECIST 1.1 criteria.~* Adequate organ and marrow function as evidenced by:~  * White blood cell count ≥ 2000/μL.~ * Neutrophils ≥ 1000/μL.~ * Platelets ≥ 60 x 103/μL.~ * Hemoglobin ≥ 9.0 g/dL.~ * Creatinine Clearance \> 40 mL/min.~ * AST and ALT ≤ 5 X ULN~ * Bilirubin ≤ 2 mg/dL~ * INR ≤ 1.8.~ * Albumin ≥ 3.0 g/dL~* Willing and able to comply with immune-monitoring sample collection and required study follow-up.~Exclusion Criteria:~* Any history of hepatic encephalopathy~* Any prior (within 6 months) or current clinical ascites.~* Any history of clinically meaningful variceal bleeding within the last three months.~* Active coinfection with both hepatitis B and C or hepatitis D infection in subjects with hepatitis B~* Occlusive main trunk portal vein thrombosis or absence of intrahepatic portal blood flow if patient carries a portocaval shunt.~* Prior malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured.~* Any autoimmune disease that may require immunosuppressive therapy.~* Any severe organ disease~* Prior therapy with any drug specifically targeting T-cell costimulation or checkpoint pathways.~* Prior organ allograft or allogeneic bone marrow transplantation~* Active bacterial or fungal infections within 7 days of study entry.~* Any condition requiring systemic treatment with corticosteroids or other immunosuppressive medications within 14 days of study drug administration.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SIRT and Nivolumab (Type: EXPERIMENTAL): SIRT (selective internal radiation therapy) will be performed in a single session using SIR-Spheres resin microspheres. After 3 weeks, nivolumab 240 mg every 2 weeks will be initiated

Based on this trial design, predict the completion outcome and termination type (if applicable).